The treatment of leg ulcers in diabetic patients with
becaplermin gel (a recombinant human PDGF approved for topical applications) stimulates complete healing and shortens the time to healing [63].
[108.] VJ Mandracchia, SM Sanders, JA Frerichs, The use of
becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers: a retrospective analysis, Clin Podiatr Med Surg, 18, 189-209, (2001).
Schwab, "Efficacy and safety of
becaplermin (recombinant human platelet-derived growth factor-BB)in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies," Wound Repair and Regeneration, vol.
Smith & Nephew, the global medical technology business, today announces that REGRANEX (
becaplermin) Gel, 0.01%, OASIS Wound Matrix, and OASIS Ultra Tri-Layer Matrix have been granted the American Podiatric Medical Association (APMA) Seal of Approval.
In addition, for the past 15 years, Regranex (
becaplermin) has been the only pharmacologic wound-healing agent available; however, it is rarely used due a perceived lack of efficacy.
Recombinant human platelet-derived growth factor-BB (
becaplermin) for healing chronic lower extremity diabetic ulcers: An open-label clinical evaluation of efficacy.
Cost-effectiveness of
becaplermin for nonhealing neuropathic diabetic foot ulcers.
(14) So, although the application of topical growth factors (eg,
becaplermin) to wounds has been an important development, it is not the universal panacea that was initially hoped.
The advanced biologic therapies reviewed included bilayered living skin substitute (Apligraf), recombinant human platelet derived growth factor (
becaplermin [Regranex]), and platelet releasate (Procuren).
The advanced biologic therapies reviewed in this study included bilayered living skin substitute (Apligraf), recombinant human platelet-derived growth factor (
becaplermin [Regranex]), and platelet releasate (Procuren).
Food and Drug Administration today announced the addition of a boxed warning to the label of Regranex Gel 0.01% (
becaplermin) to address the increased risk of cancer mortality in patients who use or more tubes of the product.
Review of records during the phase III trials of
becaplermin demonstrated that diabetic foot ulcers in treatment centers where debridements were performed most frequently were statistically more likely to heal than in centers performing the least frequent debridements[16] (Table 3).
